The EPO’s Enlarged Board of Appeal has now issued its written decision in referral G2/21, which questioned the admissibility of post-filed data and the overall patentability concept of “plausibility”. The outcome of this referral has been eagerly anticipated, especially in the life sciences and chemistry sectors where post-filed data is often crucial.
Does this decision conclude one of the EPO’s most significant legal challenges of the last few decades?
In this fast-response webinar, we will:
set out the background to the referral, the referred questions, and the answers;
present examples illustrating the interplay between plausibility and post-filed data;
consider the implications of this decision for applicants and attorneys; and
provide top tips for patent drafting in order to minimise the chances of issues during prosecution or in post-grant proceedings.
Join us to stay ahead!
If you have any questions in the meantime, please don’t hesitate to email our events team.